stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Revenue growth
Neurocrine Biosciences, Inc.'s revenue growth over the twelve months to 30 September 2026 was 38.0%, up 16.5 percentage points from fiscal 2025 (21.5%). Over the past ten years it has ranged from −24.1% (fiscal 2016) to 977.5% (fiscal 2017); the current reading is higher than 27% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 5.22% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 21.5% | (3.36) |
| FY2024 | 24.8% | (1.95) |
| FY2023 | 26.8% | (4.58) |
| FY2022 | 31.3% | 22.96 |
| FY2021 | 8.38% | (24.33) |
| FY2020 | 32.7% | (41.96) |
| FY2019 | 74.7% | (104.49) |
| FY2018 | 179.2% | (798.35) |
| FY2017 | 977.5% | 1,001.63 |
| FY2016 | −24.1% | (601.37) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 41.2% | 1.75 |
| Jun 2026 | 39.5% | (2.76) |
| Mar 2026 | 42.3% | 13.92 |
| Dec 2025 | 28.3% | 0.55 |
| 36 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 58.2% |
| NBIX Neurocrine Biosciences, Inc. | 38.0% |
| ALKS Alkermes plc compare | 15.3% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. compare | 4.27% |
| UTHR United Therapeutics Corporation compare | 1.89% |
| ZTS Zoetis Inc. compare | 1.58% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on NBIX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement